首页>投融资
eGenesis
D轮
eGenesis Inc is a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage.In November 2019, the company had raised 100 million through series B financing
基本信息
-
公司全称eGenesis Inc
-
类型异种器官移植临床应用服务提供商
-
产业领域生物药、研发制造服务
-
公司人数15~50人
-
地址300 Technology Square Suite 301 CAMBRIDGE MASSACHUSETTS 02139; US;
-
联系电话
-
邮箱info@egenesisbio.com
-
成立时间2015-01-01
投融资
-
2024-09-04D轮1.91亿美元Lux CapitalARCH Ventures PartnersKhosla VenturesFarallon Capital ManagementAlta Partners德国费森尤斯集团Leaps by BayerEisai InnovationDaVita Venture GroupNatco PharmaParkwood
-
2021-03-02C轮1.25亿美元Samsara BioCapitalCatalio Capital ManagementFarallon Capital ManagementInvusBayerKhosla VenturesPolaris PartnersHBM HealthcareARCH Venture PartnersAlta PartnersAltium CapitalIrving InvestorsLifeSci Venture PartnersOsage University PartnersMonashee Investment ManagementWellington Partners德国费森尤斯集团
-
2019-11-07B轮1亿美元Leaps by BayerKhosla VenturesARCH Venture PartnersAlta PartnersWellington Partners德国费森尤斯集团Biomatics Capital Partners
-
2017-03-17A轮3800万美元Khosla VenturesARCH Venture PartnersAlta PartnersAlexandria Venture InvestmentsBiomatics Capital Partners
- 加载更多
相关投融资企业
D轮
eGenesis Inc is a biotechnology company utilizing breakthrough gene editing technologies for the development of effective human-compatible organs to address the global organ shortage.In November 2019, the company had raised 100 million through series B financing
C轮
Kiyatec Llc is a developer of advanced 3D cell culture technology designed to predict patient response to therapies before the treatment begins. The company's technology utilizes patients' living tumour cells to create phenotypic 3D cell-based models for drug response profiling and analyzing cell-material interactions, enabling medical practitioners to isolate effective treatments for patients having cancer and tumours.In December 2022, Kiyatec Inc closed its Series C funding round totalling US$18 million
未透露
Kiyatec Llc is a developer of advanced 3D cell culture technology designed to predict patient response to therapies before the treatment begins. The company's technology utilizes patients' living tumour cells to create phenotypic 3D cell-based models for drug response profiling and analyzing cell-material interactions, enabling medical practitioners to isolate effective treatments for patients having cancer and tumours.In December 2022, Kiyatec Inc closed its Series C funding round totalling US$18 million
浙公网安备33011002015279
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息